Biosimilars

 

The Benefits of Anti-TNF Biosimilars

August 18, 2020

Authors of a review say biosimilars would improve treatment, not just reduce cost.

Oncology Care Model Spurs Use of Biosimilar Filgrastim

August 17, 2020

Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.

When Will Biosimilars Start Making a Serious Difference in Oncology?

August 05, 2020

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.

Is the Biosimilars Waiting Game Finally Over?

July 30, 2020

Advocates say a number of regulatory changes could help bring more of these products on to the market.

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Biosimilars for Cancer an 'Emerging Success' Says NCCN's Koh

July 09, 2020

Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.

FDA Approves Hulio, the Sixth Biosimilar to Humira

July 08, 2020

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

Biosimilars Fan Club Includes Free-Market Conservatives

July 06, 2020

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars

July 02, 2020

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

Challenges of Developing the Next Generation of Biosimilars

June 04, 2020

Proving therapeutic equivalence is a major hurdle.

Understanding Biosimilar Development and Approvals

June 04, 2020

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

11 Trends Influencing Biosimilars in 2020

May 18, 2020

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

Health Execs: Here are 5 Important Takeaways About the Current Situation With Biosimilars

May 18, 2020

Just as we’ve seen the entire healthcare landscape change in 2020 because of  COVID-19, the world of biosimilars is ever-changing. 

Biosimilars in the Pipeline

January 02, 2020

Several biosimilars will come to market within the next few years.

Biosimilar Availability May Impact Drug Pricing

January 02, 2020

Study finds that biologics that faced competition from biosimilars showed reductions in net prices and leveling off of list price increases.

3 Ways Insurers Can Help Promote Biosimilar Adoption

May 01, 2019

The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?

Calls for “Structural Policy Changes” for Biosimilars Market

May 01, 2019

The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.

5 Myths About Biosimilars-And the Facts

April 15, 2019

The falsehoods being spread about biosimilars that don’t match up with reality.

FDA Issues Biosimilar Naming Guidance

April 01, 2019

The FDA issued a lengthy statement on biosimilar naming conventions-but industry groups worry it could disincentivize biosimilar development.